Protara Therapeutics (TARA) Cash & Equivalents (2013 - 2026)

Protara Therapeutics' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $14.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 83.89% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (down 83.89% YoY), while the FY2025 annual figure was $49.7 million, down 69.5% from the prior year.
• Cash & Equivalents was $14.7 million for Q1 2026 at Protara Therapeutics, down from $49.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $162.8 million in Q4 2024 to a low of $12.6 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $48.0 million across 5 years, with a median of $34.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents jumped 311.25% in 2024, then tumbled 83.89% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $24.1 million in 2022, then surged by 64.07% to $39.6 million in 2023, then surged by 311.25% to $162.8 million in 2024, then sank by 69.5% to $49.7 million in 2025, then slumped by 70.32% to $14.7 million in 2026.
• The last three Cash & Equivalents figures came in at $14.7 million (Q1 2026), $49.7 million (Q4 2025), and $12.6 million (Q3 2025), per Business Quant data.